Leerink Partnrs Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold
MarketBeatLeerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday.
Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday.